このページの翻訳は実験的なもので、現在開発中です。お待ちしております
Qiagen バランスシートの健全性
財務の健全性 基準チェック /66
Qiagenの総株主資本は$3.4B 、総負債は$1.5Bで、負債比率は42.8%となります。総資産と総負債はそれぞれ$5.6Bと$2.2Bです。 Qiagenの EBIT は$166.6Mで、利息カバレッジ比率-6です。現金および短期投資は$890.2Mです。
主要情報
42.8%
負債資本比率
US$1.46b
負債
| インタレスト・カバレッジ・レシオ | -6x |
| 現金 | US$890.24m |
| エクイティ | US$3.41b |
| 負債合計 | US$2.18b |
| 総資産 | US$5.58b |
財務の健全性に関する最新情報
Here's Why Qiagen (NYSE:QGEN) Can Manage Its Debt Responsibly
Mar 20
These 4 Measures Indicate That Qiagen (NYSE:QGEN) Is Using Debt Reasonably Well
Dec 08Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly
Sep 04Is Qiagen (NYSE:QGEN) Using Too Much Debt?
May 23Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly
Feb 15We Think Qiagen (NYSE:QGEN) Can Stay On Top Of Its Debt
Oct 31Recent updates
An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 32% Undervalued
Sep 24With Qiagen N.V. (NYSE:QGEN) It Looks Like You'll Get What You Pay For
May 21Qiagen N.V. Just Recorded A 6.9% EPS Beat: Here's What Analysts Are Forecasting Next
May 03Here's Why Qiagen (NYSE:QGEN) Can Manage Its Debt Responsibly
Mar 20Calculating The Intrinsic Value Of Qiagen N.V. (NYSE:QGEN)
Feb 13Qiagen N.V.'s (NYSE:QGEN) Price Is Out Of Tune With Earnings
Jan 23These 4 Measures Indicate That Qiagen (NYSE:QGEN) Is Using Debt Reasonably Well
Dec 08An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 41% Undervalued
Oct 24Qiagen: No Upsides Slated In FY'23 In Core Business Lines, Reiterate Hold
Sep 09Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly
Sep 04Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)
Jul 17Qiagen: Major Asset Growth Needed In Post-Covid World
Jun 22Is Qiagen (NYSE:QGEN) Using Too Much Debt?
May 23Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)
Apr 18Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly
Feb 15Qiagen: Strong Q4, Derisked Portfolio, Fairly Valued
Feb 14Qiagen Non-GAAP EPS of $0.53, revenue of $498M, FY23 guidance initiated
Feb 07If EPS Growth Is Important To You, Qiagen (NYSE:QGEN) Presents An Opportunity
Jan 18Qiagen, Helix partner to advance NGS companion diagnostics in hereditary diseases
Jan 06A Look At The Fair Value Of Qiagen N.V. (NYSE:QGEN)
Jan 04Qiagen's test gets FDA nod for companion diagnostic to Mirati's cancer drug Krazati
Dec 13Qiagen Non-GAAP EPS of $0.53 beats by $0.08, revenue of $500M beats by $17.91M
Nov 07We Think Qiagen (NYSE:QGEN) Can Stay On Top Of Its Debt
Oct 31Qiagen stock down after BHF downgrades rating to Neutral
Oct 10Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)
Oct 04Qiagen to develop companion diagnostic for Neuron23's Parkinson's disease drug candidate
Sep 14Does Qiagen (NYSE:QGEN) Deserve A Spot On Your Watchlist?
Aug 25Is Qiagen (NYSE:QGEN) Using Too Much Debt?
Jul 28Qiagen Fails To Justify Inclusion In Long-Biased, Balanced Macro Portfolio
Jul 15Is Qiagen N.V. (NYSE:QGEN) Trading At A 36% Discount?
Jun 29財務状況分析
短期負債: QGENの 短期資産 ( $1.8B ) が 短期負債 ( $1.0B ) を超えています。
長期負債: QGENの短期資産 ( $1.8B ) が 長期負債 ( $1.1B ) を上回っています。
デット・ツー・エクイティの歴史と分析
負債レベル: QGENの 純負債対資本比率 ( 18.5% ) は 満足できる 水準であると考えられます。
負債の削減: QGENの負債対資本比率は、過去 5 年間で67.5%から42.8%に減少しました。
債務返済能力: QGENの負債は 営業キャッシュフロー によって 十分にカバー されています ( 33.4% )。
インタレストカバレッジ: QGEN支払う利息よりも稼ぐ利息の方が多いので、利息支払い の補償は問題になりません。